We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Arginase Found to Be Good Target for Asthma Therapy

By Biotechdaily staff writers
Posted on 03 Jul 2003
Researchers into the molecular basis for asthma have identified a group of 219 "signature genes” involved in the development of both asthma and some allergic diseases, with arginase in particular appearing to be a good target for therapy.

Investigators at Children's Hospital Medical Center (Cincinnati, OH, USA) obtained lung tissue from mice with experimental models of asthma induced by different allergens. More...
The tissues were analyzed by DNA microarray techniques. Lung tissue from asthmatic mice differed from that of normal animals by altered expression in 6.5% of the genome (representing 219 separate genes).

"Each gene may represent a target for drug development,” explained senior author Dr. Marc Rothenberg, director of allergy and immunology at Children's Hospital Medical Center. "But one gene in particular, arginase, regulates pathways that we think are critical in an asthmatic reaction. Regardless of the specific allergen, arginase seems to be involved. We hope to come up with a treatment for asthma by targeting arginase.”

The findings were published in the July 2003 issue of the Journal of Clinical Investigation. "With the publishing of these results, the asthma signature genes will now become available to the public over the worldwide web,” said Dr. Rothenberg. "It is our hope that the release of these results will fuel the pharmaceutical industry, as well as other researchers, to take new approaches in asthma research.”


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.